How We Help Researchers
We are happy to share our robust data set with research collaborators in order to co-publish findings. We have over 17 thousand EPIK850k longitudinal methylation profiles from consenting patients, including covariates like disease history and medication use.
Need specialized data for your study? We can reach out to our patient cohort to get additional information.
When Cornell University researchers published on COVID-19 early in the pandemic, we thought they might be interested in using our data on the topic for additional investigation.
Together, we decided to look at longitudinal methylation changes before and after COVID-19 and mRNA vaccines. TruDiagnostic supplied longitudinal datasets on over 60 patients.
Cornell took the lead on analyzing the data, but was later joined by the Yale research team for additional insight. The final paper was submitted and published in 2021.
We love to partner with academic institutions and sponsor research endeavors, in exchange for exclusivity on intellectual property.
We may be able to work together at a discount, or even no cost to you!
In our collaboration with Harvard University researchers, we agreed to use a multi-omic dataset to generate the most robust phenotypic and death predictor to date.
After initiating a multi-million dollar sponsored research agreement with Channing lab and Partners Biobank, TruDiagnostic started testing the 5,000 samples from the biobank for metabolomic and epigenomic data. We recently began testing 1,500 plasma samples with our TruDiagnostic Imprintome Chip, aided by the Seer Proteograph.
With 1,488 defined ICRs and 23,000 CpGs; as of May this is the third-largest proteomic analysis project in the world, using the most complete human imprintome array in the world.
By the end of 2022, we hope to create a Proteomic Age Clock, Metabolomic Age Clock, Epigenetic Phenotypic Multiomic Age Clock, and a Epigenetic Death Trained Multiomic Clock
TruDiagnostic is sponsoring this effort, in exchange for exclusivity on IP developed through the project.
For joint research endeavors in research partnerships, we can provide discounted or free methylation testing for joint investigations.
Scientists at the Ohio State University Cancer Center reached out to test 700 samples at our lab, from cancer patients. Given the other covariate data they had, TruDiagnostic offered to sponsor 50% of the testing cost in exchange for research collaboration.
We will now be processing over 1,200 samples with the expanded budget, with shared data for analysis on the methylation and aging associations with clinical outcomes.
Once analysis is complete, we plan to publish this analysis on the effects of epigenetic age and cancer. We also hope to discover novel areas of methylation change with senescent data and create T-Cell specific aging algorithms.
TruDiagnostic started commercial epigenetic age testing in July 2020. Since then, we have tested over 15,000 patients on the EPIC850k array.
Our 20,000 sq ft, CLIA-Certified laboratory has hosted over 30 institutional research board approved clinical trials. Our team has developed 3 custom methylation arrays for aging and the imprintome as of May 2022.
We have developed custom deconvolution algorithms, telomere estimators, mitotic clocks, multi-omic age clocks, and more.
How does it work?
How does it work?